“`html
A surge in Mycoplasma pneumoniae infections,particularly among children,is sweeping across Canada and beyond,and researchers are now pinpointing shifts in the bacteria’s genetic makeup.Detection rates in one Ontario region have climbed as high as 30% as May 2024, raising concerns about treatment effectiveness.
Understanding the Rise in ‘Walking Pneumonia’ and Evolving Resistance
Table of Contents
Mycoplasma pneumoniae, often called “walking pneumonia,” is a common cause of respiratory infections, especially in kids. While usually mild, it can sometimes lead to more serious pneumonia, accounting for roughly 4% to 8% of community-acquired bacterial pneumonia cases. Macrolide antibiotics are typically the first line of defense, but increasing resistance is complicating matters.
What’s driving the increase in Mycoplasma pneumoniae cases? The lifting of COVID-19 restrictions in 2023 appears to have created conditions for a rebound in infections, as people’s immunity waned and social mixing increased. This has led to a delayed but significant surge in cases worldwide.
Researchers at the Hamilton Regional Laboratory Medicine Program in Hamilton, ontario, investigated macrolide resistance and the genetic characteristics of M. pneumoniae strains during the 2024-2025 outbreak. They compared their findings to strains collected before the COVID-19 pandemic to understand how the bacteria has changed.
Tracking the Outbreak: Testing and Genetic Analysis
Between January 2024 and April 2025, the lab analyzed nearly 4,300 nasal swab samples from over 3,700 patients. A total of 417 samples tested positive for M.pneumoniae. Researchers used PCR genotyping to identify macrolide resistance and nanopore sequencing to analyze the P1 cytadhesin gene, a key factor in how the bacteria attaches to cells in the respiratory tract. They also examined a smaller set of samples from 2013-2020 for comparison.
On average, 14.2% of patients tested positive for M. pneumoniae in 2024,a dramatic increase from 0.34% in 2022 and 0.36% in 2023. positivity rates peaked at 22.5% in September 2024 before declining to below 5% by January 2025, even with continued testing. Macrolide resistance was found in 11.8% of positive samples with a high of 50% in July 2024.
Resistance Patterns and Age Differences
The genetic analysis revealed a single mutation, A2063G, consistently linked to high
macrolide resistance. Further analysis showed a shift in the dominant P1 cytadhesin types, with a rise in strains expressing P1-non-expressing phenotypes.This is significant as P1 cytadhesin plays a crucial role in the bacteria’s ability to infect cells, and changes in its expression could affect disease severity and transmission.
Interestingly, the researchers observed age-related differences in resistance patterns. Macrolide resistance was more common in older children and adults compared to younger children. This suggests that prior antibiotic exposure or differences in immune responses may contribute to the progress of resistance.
Implications for Treatment and Future Research
The findings highlight the need for updated treatment guidelines and ongoing surveillance of M. pneumoniae strains. The increasing prevalence of macrolide resistance suggests that alternative antibiotics, such as tetracyclines or fluoroquinolones, may be necesary in some cases. However, these alternatives also have potential side effects and should be used judiciously.
